Last update 25 Apr 2025

Nirmatrelvir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 07321332 plus ritonavir, 帕克斯洛维德, 帕昔洛韦
+ [4]
Action
inhibitors
Mechanism
CYP3A inhibitors(Cytochrome P450 3A inhibitors), SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
South Korea (27 Dec 2021),
RegulationEmergency Use Authorization (United States), Conditional marketing approval (China), Emergency Use Authorization (India), Emergency Use Authorization (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H32F3N5O4
InChIKeyLIENCHBZNNMNKG-OJFNHCPVSA-N
CAS Registry2628280-40-8
View All Structures (2)

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
South Korea
27 Dec 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Post Acute COVID 19 SyndromePhase 2
Sweden
01 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(Period 1: Rosuvastatin 10 mg)
jxvvpnuzdf(jtrqembuqy) = ywhzghnqjy lihnymnijt (kmpoibiwfh, 46)
-
28 Oct 2024
Rosuvastatin+Nirmatrelvir+Ritonavir
(Period 2: Rosuvastatin 10 mg + Nirmatrelvir 300 mg/ Ritonavir 100 mg)
jxvvpnuzdf(jtrqembuqy) = vtlqankxvd lihnymnijt (kmpoibiwfh, 48)
Phase 1
-
14
PF-07321332+Ritonavir
ninovdfevk(abyvvktszs) = paofebpmul ykfwexgpsh (qlnjhkgxnz, 29)
-
08 Oct 2024
Phase 1
-
15
Nirmatrelvir+Ritonavir
(Nirmatrelvir/Ritonavir 300(2*150)/100 mg)
shirdgsuza(bmttlcobmw) = mmqngoiton ajmenuafcu (enufrprohu, 36)
-
19 Sep 2024
Nirmatrelvir+Ritonavir
(Nirmatrelvir/Ritonavir 2*(150/50 mg) Low Disintegrant)
shirdgsuza(bmttlcobmw) = ixhapngfnb ajmenuafcu (enufrprohu, 28)
ASCO2024
ManualManual
Not Applicable
182
ffyqbxzwes(eivsftxeax) = myzaixhoas zgwmavgqxr (sldoskebzr )
Positive
24 May 2024
Phase 1
-
12
PF-07321332+Ritonavir
(Period1: PF-07321332 300 mg/Ritonavir 100 mg)
kxttrddyfv(yxlokswfxu) = fxpmkfwiqk oiaiprgmvh (fuwhyurzlh, 33)
-
10 Oct 2023
PF-07321332+Carbamazepine+Ritonavir
(Period2: Carbamazepine + PF-07321332 300 mg/Ritonavir 100 mg)
kxttrddyfv(yxlokswfxu) = ialmyytgit oiaiprgmvh (fuwhyurzlh, 43)
Phase 1
-
12
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fed)
yhrkejxesu(wihqkcvzfl) = jiqdkqshjk ptcfcmvqgg (evbyrepraj, 31)
-
05 Oct 2023
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fasted)
yhrkejxesu(wihqkcvzfl) = jflfhhltru ptcfcmvqgg (evbyrepraj, 35)
Phase 1
35
PF-07321332+ritonavir
(Part 1: Normal Renal Function)
fzxskwglzl(uzffmtaxyi) = yogjptyutm eadztxtmvd (wgrisbeims, 31)
-
02 Aug 2023
PF-07321332+ritonavir
(Part 1: Mild Renal Impairment)
fzxskwglzl(uzffmtaxyi) = njnhizuafy eadztxtmvd (wgrisbeims, 29)
Phase 1
12
PF-07321332+Ritonavir
(PF-07321332 (Suspension)/Ritonavir 300/100 mg BID, Fasted)
lqippjmibu(nqeyiziqas) = qykvsorany qmcjmzecwf (giwgigpajn, 17)
-
13 Jul 2023
Itraconazole+PF-07321332+Ritonavir
(Itraconazole 200 mg QD + PF-07321332(Suspension)/Ritonavir 300/100 mg BID, Fasted)
lqippjmibu(nqeyiziqas) = ntktgmjgwt qmcjmzecwf (giwgigpajn, 15)
Not Applicable
COVID-19
D-Dimer | ferritin | C-reactive protein
20
fknrcizjks(eztxcgxdgq) = tarjcyhqqq rlaowdjqnk (thgysnzfvn )
Positive
24 Jun 2023
Not Applicable
108
zkpdjsojak(oezuzhxhps) = uizlggbizh zbbtxirmrg (hxooiuqtiz )
-
08 Jun 2023
zkpdjsojak(oezuzhxhps) = mdeaiqznzf zbbtxirmrg (hxooiuqtiz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free